

Blandford

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 0.84 | 1 | NC* | Male | 0.55 | 0 | NC* |
| Female | 0.23 | 0 | NC* | Female | 0.34 | 1 | NC* |
| Total | 1.07 | 1 | NC* | Total | 0.89 | 1 | NC* |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 0.28 | 0 | NC* | Male | 0.16 | 0 | NC* |
| Female | 0.18 | 0 | NC* | Female | 0.11 | 1 | NC* |
| Total | 0.47 | 0 | NC* | Total | 0.28 | 1 | NC* |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 0.06 | 0 | NC* | Male | 0.67 | 1 | NC* |
| Female | 4.48 | 4 | NC* | Female | 0.46 | 0 | NC* |
| Total | 4.54 | 4 | NC* | Total | 1.14 | 1 | NC* |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 0.28 | 0 | NC* | Male | 0.59 | 1 | NC* |
| | | | | Female | 0.21 | 0 | NC* |
| | | | | Total | 0.80 | 1 | NC* |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 2.11 | 1 | NC* | Female | 0.53 | 0 | NC* |
| Female | 1.40 | 2 | NC* | | | | |
| Total | 3.51 | 3 | NC* | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.32 | 0 | NC* | Male | 0.34 | 0 | NC* |
| Female | 0.07 | 0 | NC* | Female | 0.25 | 0 | NC* |
| Total | 0.40 | 0 | NC* | Total | 0.59 | 0 | NC* |
| <u>Hodgkin's Disease</u> | | | | <u>Prostate</u> | | | |
| Male | 0.12 | 0 | NC* | Male | 5.24 | 1 | NC* |
| Female | 0.09 | 1 | NC* | | | | |
| Total | 0.21 | 1 | NC* | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | <u>Stomach</u> | | | |
| Male | 0.52 | 0 | NC* | Male | 0.36 | 1 | NC* |
| Female | 0.25 | 0 | NC* | Female | 0.15 | 0 | NC* |
| Total | 0.77 | 0 | NC* | Total | 0.50 | 1 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.31 | 0 | NC* | Male | 0.16 | 1 | NC* |
| Female | 0.07 | 0 | NC* | | | | |
| Total | 0.37 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.37 | 0 | NC* | Male | 0.11 | 0 | NC* |
| Female | 0.22 | 0 | NC* | Female | 0.25 | 0 | NC* |
| Total | 0.59 | 0 | NC* | Total | 0.36 | 0 | NC* |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Male | 0.19 | 0 | NC* | Female | 0.88 | 2 | NC* |
| Female | 0.06 | 0 | NC* | | | | |
| Total | 0.25 | 0 | NC* | | | | |
| <u>Lung and Bronchus</u> | | | | <u>All Sites / Types</u> | | | |
| Male | 2.77 | 1 | NC* | Male | 17.21 | 11 | 64 |
| Female | 1.75 | 1 | NC* | Female | 13.11 | 14 | 107 |
| Total | 4.52 | 2 | NC* | Total | 30.33 | 25 | 82 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs / Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Bolton

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|---|------------|------------|------------|--------------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 2.10 | 0 | NC* | Male | 1.57 | 2 | NC* |
| Female | 0.64 | 1 | NC* | Female | 1.07 | 2 | NC* |
| Total | 2.73 | 1 | NC* | Total | 2.64 | 4 | NC* |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 0.83 | 1 | NC* | Male | 0.43 | 0 | NC* |
| Female | 0.56 | 0 | NC* | Female | 0.33 | 0 | NC* |
| Total | 1.40 | 1 | NC* | Total | 0.76 | 0 | NC* |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 0.15 | 0 | NC* | Male | 1.89 | 0 | NC* |
| Female | 14.03 | 8 | 57 | Female | 1.34 | 0 | NC* |
| Total | 14.17 | 8 | 56 | Total | 3.23 | 0 | NC* |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 0.88 | 2 | NC* | Male | 1.76 | 1 | NC* |
| | | | | Female | 0.64 | 0 | NC* |
| | | | | Total | 2.39 | 1 | NC* |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 5.31 | 1 | NC* | Female | 1.66 | 6 | 362 #+ |
| Female | 3.91 | 2 | NC* | | | | |
| Total | 9.22 | 3 | NC* | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.91 | 0 | NC* | Male | 0.91 | 0 | NC* |
| Female | 0.19 | 0 | NC* | Female | 0.69 | 0 | NC* |
| Total | 1.10 | 0 | NC* | Total | 1.60 | 0 | NC* |
| <u>Hodgkin's Disease</u> | | | | <u>Prostate</u> | | | |
| Male | 0.38 | 0 | NC* | Male | 13.98 | 11 | 79 |
| Female | 0.26 | 0 | NC* | | | | |
| Total | 0.64 | 0 | NC* | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | <u>Stomach</u> | | | |
| Male | 1.47 | 0 | NC* | Male | 0.93 | 1 | NC* |
| Female | 0.74 | 2 | NC* | Female | 0.42 | 0 | NC* |
| Total | 2.21 | 2 | NC* | Total | 1.35 | 1 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.88 | 1 | NC* | Male | 0.54 | 0 | NC* |
| Female | 0.21 | 0 | NC* | | | | |

| | | | |
|---|-------|----|-----|
| Total | 1.09 | 1 | NC* |
| <u>Leukemia</u> | | | |
| Male | 1.02 | 2 | NC* |
| Female | 0.68 | 1 | NC* |
| Total | 1.70 | 3 | NC* |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | |
| Male | 0.53 | 0 | NC* |
| Female | 0.16 | 0 | NC* |
| Total | 0.69 | 0 | NC* |
| <u>Lung and Bronchus</u> | | | |
| Male | 7.31 | 8 | 109 |
| Female | 5.02 | 4 | NC* |
| Total | 12.34 | 12 | 97 |

| | | | |
|---|-------|----|-------|
| <u>Thyroid</u> | | | |
| Male | 0.34 | 0 | NC* |
| Female | 0.78 | 1 | NC* |
| Total | 1.12 | 1 | NC* |
| <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Female | 2.73 | 3 | NC* |
| <u>All Sites / Types</u> | | | |
| Male | 46.27 | 31 | 67 #- |
| Female | 39.46 | 34 | 86 |
| Total | 85.73 | 65 | 76 #- |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Boston

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---------------------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 266.83 | 213 | 80 ^- | Male | 180.29 | 169 | 94 |
| Female | 116.61 | 91 | 78 #- | Female | 158.83 | 141 | 89 |
| Total | 383.44 | 304 | 79 ^- | Total | 339.12 | 310 | 91 |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 97.47 | 81 | 83 | Male | 49.37 | 57 | 115 |
| Female | 82.66 | 58 | 70 ~- | Female | 50.20 | 58 | 116 |
| Total | 180.14 | 139 | 77 ~- | Total | 99.57 | 115 | 115 |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 17.04 | 14 | 82 | Male | 233.37 | 280 | 120 ~+ |
| Female | 1856.67 | 1691 | 91 ^- | Female | 220.96 | 225 | 102 |
| Total | 1873.71 | 1705 | 91 ^- | Total | 454.33 | 505 | 111 #+ |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 130.47 | 173 | 133 ^+ | Male | 173.48 | 248 | 143 ^+ |
| | | | | Female | 90.62 | 117 | 129 ~+ |
| | | | | Total | 264.10 | 365 | 138 ^+ |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 670.11 | 743 | 111 ~+ | Female | 223.36 | 203 | 91 |
| Female | 735.38 | 793 | 108 #+ | | | | |
| Total | 1405.49 | 1536 | 109 ^+ | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 94.25 | 126 | 134 ~+ | Male | 104.55 | 110 | 105 |

| | | | |
|---|---------|------|--------|
| Female | 37.66 | 55 | 146 ~+ |
| Total | 131.91 | 181 | 137 ^+ |
| <u>Hodgkin's Disease</u> | | | |
| Male | 58.44 | 52 | 89 |
| Female | 48.70 | 43 | 88 |
| Total | 107.14 | 95 | 89 |
| <u>Kidney and Renal Pelvis</u> | | | |
| Male | 155.52 | 154 | 99 |
| Female | 107.20 | 122 | 114 |
| Total | 262.72 | 276 | 105 |
| <u>Larynx</u> | | | |
| Male | 86.74 | 125 | 144 ^+ |
| Female | 25.21 | 41 | 163 ~+ |
| Total | 111.95 | 166 | 148 ^+ |
| <u>Leukemia</u> | | | |
| Male | 125.02 | 114 | 91 |
| Female | 107.83 | 110 | 102 |
| Total | 232.85 | 224 | 96 |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | |
| Male | 57.38 | 88 | 153 ^+ |
| Female | 26.76 | 31 | 116 |
| Total | 84.14 | 119 | 141 ^+ |
| <u>Lung and Bronchus</u> | | | |
| Male | 832.44 | 992 | 119 ^+ |
| Female | 723.07 | 816 | 113 ^+ |
| Total | 1555.52 | 1808 | 116 ^+ |

| | | | |
|---|----------|-------|--------|
| Female | 126.13 | 132 | 105 |
| Total | 230.68 | 242 | 105 |
| <u>Prostate</u> | | | |
| Male | 1540.65 | 1761 | 114 ^+ |
| <u>Stomach</u> | | | |
| Male | 114.34 | 167 | 146 ^+ |
| Female | 80.65 | 94 | 117 |
| Total | 195.00 | 261 | 134 ^+ |
| <u>Testis</u> | | | |
| Male | 99.77 | 66 | 66 ^- |
| <u>Thyroid</u> | | | |
| Male | 41.74 | 39 | 93 |
| Female | 123.49 | 134 | 109 |
| Total | 165.23 | 173 | 105 |
| <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Female | 341.84 | 322 | 94 |
| <u>All Sites / Types</u> | | | |
| Male | 5392.18 | 6125 | 114 ^+ |
| Female | 5849.23 | 5942 | 102 |
| Total | 11241.41 | 12067 | 107 ^+ |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Bourne

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | |
| Male | 13.44 | 13 | 97 |
| Female | 4.73 | 8 | 169 |
| Total | 18.17 | 21 | 116 |
| <u>Brain and Other Central Nervous System</u> | | | |
| Male | 3.83 | 6 | 157 |
| Female | 2.86 | 1 | NC* |
| Total | 6.69 | 7 | 105 |
| <u>Breast</u> | | | |

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--------------------------------------|------------|------------|------------|
| <u>Melanoma of Skin</u> | | | |
| Male | 7.56 | 11 | 145 |
| Female | 5.23 | 9 | 172 |
| Total | 12.79 | 20 | 156 |
| <u>Multiple Myeloma</u> | | | |
| Male | 2.46 | 1 | NC* |
| Female | 2.04 | 3 | NC* |
| Total | 4.49 | 4 | NC* |
| <u>Non-Hodgkin's Lymphoma</u> | | | |

| | | | |
|--------|-------|----|-----|
| Male | 0.82 | 1 | NC* |
| Female | 68.65 | 65 | 95 |
| Total | 69.47 | 66 | 95 |

Cervix Uteri

| | | | |
|--------|------|---|-----|
| Female | 3.79 | 5 | 132 |
|--------|------|---|-----|

Colon / Rectum

| | | | |
|--------|-------|----|-----|
| Male | 33.61 | 37 | 110 |
| Female | 29.78 | 33 | 111 |
| Total | 63.39 | 70 | 110 |

Esophagus

| | | | |
|--------|------|----|--------|
| Male | 4.56 | 10 | 219 #+ |
| Female | 1.54 | 0 | NC* |
| Total | 6.10 | 10 | 164 |

Hodgkin's Disease

| | | | |
|--------|------|---|-----|
| Male | 1.67 | 0 | NC* |
| Female | 1.27 | 2 | NC* |
| Total | 2.94 | 2 | NC* |

Kidney and Renal Pelvis

| | | | |
|--------|-------|----|-----|
| Male | 7.17 | 6 | 84 |
| Female | 4.21 | 5 | 119 |
| Total | 11.38 | 11 | 97 |

Larynx

| | | | |
|--------|------|---|-----|
| Male | 4.08 | 6 | 147 |
| Female | 1.02 | 0 | NC* |
| Total | 5.10 | 6 | 118 |

Leukemia

| | | | |
|--------|------|---|-----|
| Male | 5.43 | 6 | 111 |
| Female | 3.91 | 3 | NC* |
| Total | 9.34 | 9 | 96 |

Liver and Intrahepatic Bile Ducts

| | | | |
|--------|------|---|--------|
| Male | 2.66 | 7 | 263 #+ |
| Female | 1.08 | 1 | NC* |
| Total | 3.74 | 8 | 214 |

Lung and Bronchus

| | | | |
|--------|-------|----|--------|
| Male | 41.65 | 43 | 103 |
| Female | 29.52 | 45 | 152 ~+ |
| Total | 71.18 | 88 | 124 |

| | | | |
|--------|-------|----|-----|
| Male | 9.73 | 8 | 82 |
| Female | 8.34 | 9 | 108 |
| Total | 18.08 | 17 | 94 |

Oral Cavity and Pharynx

| | | | |
|--------|-------|----|-----|
| Male | 7.62 | 6 | 79 |
| Female | 3.49 | 4 | NC* |
| Total | 11.10 | 10 | 90 |

Ovary

| | | | |
|--------|------|---|-----|
| Female | 7.97 | 1 | NC* |
|--------|------|---|-----|

Pancreas

| | | | |
|--------|-------|----|-----|
| Male | 5.10 | 4 | NC* |
| Female | 5.16 | 7 | 136 |
| Total | 10.26 | 11 | 107 |

Prostate

| | | | |
|------|-------|----|-----|
| Male | 78.77 | 91 | 116 |
|------|-------|----|-----|

Stomach

| | | | |
|--------|------|---|-----|
| Male | 5.54 | 7 | 126 |
| Female | 3.19 | 1 | NC* |
| Total | 8.73 | 8 | 92 |

Testis

| | | | |
|------|------|---|-----|
| Male | 2.40 | 1 | NC* |
|------|------|---|-----|

Thyroid

| | | | |
|--------|------|---|-----|
| Male | 1.37 | 1 | NC* |
| Female | 3.32 | 7 | 211 |
| Total | 4.69 | 8 | 171 |

Uteri, Corpus and Uterus, NOS

| | | | |
|--------|-------|----|-----|
| Female | 13.31 | 17 | 128 |
|--------|-------|----|-----|

All Sites / Types

| | | | |
|--------|--------|-----|--------|
| Male | 256.93 | 280 | 109 |
| Female | 220.99 | 248 | 112 |
| Total | 477.92 | 528 | 110 #+ |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Boxborough

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 1.57 | 1 | NC* | Male | 1.39 | 0 | NC* |
| Female | 0.49 | 1 | NC* | Female | 1.05 | 2 | NC* |
| Total | 2.06 | 2 | NC* | Total | 2.44 | 2 | NC* |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 0.79 | 0 | NC* | Male | 0.33 | 0 | NC* |
| Female | 0.54 | 1 | NC* | Female | 0.26 | 0 | NC* |
| Total | 1.33 | 1 | NC* | Total | 0.59 | 0 | NC* |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 0.12 | 0 | NC* | Male | 1.70 | 2 | NC* |
| Female | 12.27 | 17 | 139 | Female | 1.17 | 0 | NC* |
| Total | 12.39 | 17 | 137 | Total | 2.87 | 2 | NC* |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 0.96 | 1 | NC* | Male | 1.46 | 1 | NC* |
| | | | | Female | 0.54 | 1 | NC* |
| | | | | Total | 2.00 | 2 | NC* |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 4.02 | 7 | 174 | Female | 1.51 | 2 | NC* |
| Female | 3.03 | 2 | NC* | | | | |
| Total | 7.05 | 9 | 128 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.70 | 0 | NC* | Male | 0.70 | 1 | NC* |
| Female | 0.15 | 0 | NC* | Female | 0.53 | 0 | NC* |
| Total | 0.85 | 0 | NC* | Total | 1.23 | 1 | NC* |
| <u>Hodgkin's Disease</u> | | | | <u>Prostate</u> | | | |
| Male | 0.46 | 0 | NC* | Male | 10.43 | 6 | 58 |
| Female | 0.33 | 0 | NC* | | | | |
| Total | 0.80 | 0 | NC* | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | <u>Stomach</u> | | | |
| Male | 1.21 | 0 | NC* | Male | 0.72 | 0 | NC* |
| Female | 0.61 | 1 | NC* | Female | 0.33 | 0 | NC* |
| Total | 1.82 | 1 | NC* | Total | 1.05 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.70 | 1 | NC* | Male | 0.78 | 0 | NC* |
| Female | 0.17 | 0 | NC* | | | | |
| Total | 0.87 | 1 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.90 | 1 | NC* | Male | 0.36 | 1 | NC* |
| Female | 0.62 | 0 | NC* | Female | 0.91 | 2 | NC* |
| Total | 1.51 | 1 | NC* | Total | 1.27 | 3 | NC* |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Male | 0.43 | 0 | NC* | Female | 2.28 | 1 | NC* |
| Female | 0.12 | 0 | NC* | | | | |
| Total | 0.56 | 0 | NC* | | | | |
| <u>Lung and Bronchus</u> | | | | <u>All Sites / Types</u> | | | |
| Male | 5.59 | 1 | NC* | Male | 36.98 | 24 | 65 #- |
| Female | 4.04 | 2 | NC* | Female | 34.05 | 35 | 103 |
| Total | 9.63 | 3 | NC* | Total | 71.03 | 59 | 83 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs / Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Boxford

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---------------------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 4.38 | 3 | NC* | Male | 3.16 | 8 | 253 #+ |
| Female | 1.41 | 0 | NC* | Female | 2.23 | 2 | NC* |
| Total | 5.79 | 3 | NC* | Total | 5.39 | 10 | 185 |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 1.68 | 2 | NC* | Male | 0.88 | 0 | NC* |
| Female | 1.17 | 0 | NC* | Female | 0.71 | 0 | NC* |
| Total | 2.86 | 2 | NC* | Total | 1.59 | 0 | NC* |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 0.30 | 0 | NC* | Male | 3.83 | 5 | 130 |
| Female | 29.32 | 35 | 119 | Female | 2.88 | 2 | NC* |
| Total | 29.62 | 35 | 118 | Total | 6.71 | 7 | 104 |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 1.80 | 1 | NC* | Male | 3.54 | 2 | NC* |
| | | | | Female | 1.35 | 2 | NC* |
| | | | | Total | 4.89 | 4 | NC* |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 11.16 | 8 | 72 | Female | 3.46 | 5 | 145 |
| Female | 8.71 | 6 | 69 | | | | |
| Total | 19.87 | 14 | 70 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 1.87 | 0 | NC* | Male | 1.90 | 0 | NC* |
| Female | 0.44 | 0 | NC* | Female | 1.54 | 0 | NC* |
| Total | 2.31 | 0 | NC* | Total | 3.44 | 0 | NC* |
| <u>Hodgkin's Disease</u> | | | | <u>Prostate</u> | | | |
| Male | 0.74 | 0 | NC* | Male | 29.73 | 30 | 101 |
| Female | 0.54 | 0 | NC* | | | | |
| Total | 1.28 | 0 | NC* | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | <u>Stomach</u> | | | |
| Male | 3.00 | 1 | NC* | Male | 1.91 | 1 | NC* |
| Female | 1.57 | 3 | NC* | Female | 0.93 | 0 | NC* |
| Total | 4.57 | 4 | NC* | Total | 2.84 | 1 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.81 | 0 | NC* | Male | 1.04 | 2 | NC* |
| Female | 0.44 | 0 | NC* | | | | |

| | | | |
|------------------------|------|---|-----|
| Total | 2.25 | 0 | NC* |
| <u>Leukemia</u> | | | |
| Male | 2.06 | 1 | NC* |
| Female | 1.45 | 0 | NC* |
| Total | 3.51 | 1 | NC* |

| | | | |
|---|------|---|-----|
| <u>Liver and Intrahepatic Bile Ducts</u> | | | |
| Male | 1.10 | 0 | NC* |
| Female | 0.34 | 0 | NC* |
| Total | 1.44 | 0 | NC* |

| | | | |
|---------------------------------|-------|----|-------|
| <u>Lung and Bronchus</u> | | | |
| Male | 15.37 | 5 | 33 ~- |
| Female | 10.78 | 9 | 83 |
| Total | 26.16 | 14 | 54 #- |

| | | | |
|-----------------------|------|---|-----|
| <u>Thyroid</u> | | | |
| Male | 0.67 | 0 | NC* |
| Female | 1.59 | 2 | NC* |
| Total | 2.27 | 2 | NC* |

| | | | |
|---|------|---|-----|
| <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Female | 5.71 | 6 | 105 |

| | | | |
|---------------------------------|--------|-----|-------|
| <u>All Sites / Types</u> | | | |
| Male | 96.35 | 70 | 73 ~- |
| Female | 83.88 | 80 | 95 |
| Total | 180.22 | 150 | 83 #- |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Boylston

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--------------------------------|-------------------|-------------------|-------------------|
| <u>Bladder, Urinary</u> | | | |
| Male | 2.40 | 1 | NC* |
| Female | 0.79 | 0 | NC* |
| Total | 3.20 | 1 | NC* |

| | | | |
|--|------|---|-----|
| <u>Brain and Other Central Nervous System</u> | | | |
| Male | 0.82 | 1 | NC* |
| Female | 0.57 | 0 | NC* |
| Total | 1.39 | 1 | NC* |

| | | | |
|----------------------|-------|----|-----|
| <u>Breast</u> | | | |
| Male | 0.16 | 0 | NC* |
| Female | 13.98 | 19 | 136 |
| Total | 14.13 | 19 | 134 |

| | | | |
|----------------------------|------|---|-----|
| <u>Cervix Uteri</u> | | | |
| Female | 0.86 | 0 | NC* |

| | | | |
|------------------------------|-------|----|-----|
| <u>Colon / Rectum</u> | | | |
| Male | 6.04 | 7 | 116 |
| Female | 4.95 | 3 | NC* |
| Total | 10.99 | 10 | 91 |

| | | | |
|-------------------------|------|---|-----|
| <u>Esophagus</u> | | | |
| Male | 0.91 | 3 | NC* |

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--------------------------------|-------------------|-------------------|-------------------|
| <u>Melanoma of Skin</u> | | | |
| Male | 1.57 | 2 | NC* |
| Female | 1.08 | 0 | NC* |
| Total | 2.65 | 2 | NC* |

| | | | |
|--------------------------------|------|---|-----|
| <u>Multiple Myeloma</u> | | | |
| Male | 0.46 | 1 | NC* |
| Female | 0.37 | 0 | NC* |
| Total | 0.83 | 1 | NC* |

| | | | |
|--------------------------------------|------|---|-----|
| <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 1.96 | 2 | NC* |
| Female | 1.53 | 0 | NC* |
| Total | 3.49 | 2 | NC* |

| | | | |
|---------------------------------------|------|---|-----|
| <u>Oral Cavity and Pharynx</u> | | | |
| Male | 1.65 | 2 | NC* |
| Female | 0.67 | 0 | NC* |
| Total | 2.32 | 2 | NC* |

| | | | |
|---------------------|------|---|-----|
| <u>Ovary</u> | | | |
| Female | 1.64 | 1 | NC* |

| | | | |
|------------------------|------|---|-----|
| <u>Pancreas</u> | | | |
| Male | 0.97 | 2 | NC* |

| | | | |
|--------|------|---|-----|
| Female | 0.25 | 0 | NC* |
| Total | 1.16 | 3 | NC* |

Hodgkin's Disease

| | | | |
|--------|------|---|-----|
| Male | 0.38 | 0 | NC* |
| Female | 0.28 | 0 | NC* |
| Total | 0.66 | 0 | NC* |

Kidney and Renal Pelvis

| | | | |
|--------|------|---|-----|
| Male | 1.45 | 1 | NC* |
| Female | 0.80 | 2 | NC* |
| Total | 2.25 | 3 | NC* |

Larynx

| | | | |
|--------|------|---|-----|
| Male | 0.85 | 3 | NC* |
| Female | 0.21 | 0 | NC* |
| Total | 1.06 | 3 | NC* |

Leukemia

| | | | |
|--------|------|---|-----|
| Male | 1.07 | 1 | NC* |
| Female | 0.72 | 1 | NC* |
| Total | 1.79 | 2 | NC* |

Liver and Intrahepatic Bile Ducts

| | | | |
|--------|------|---|-----|
| Male | 0.53 | 0 | NC* |
| Female | 0.19 | 0 | NC* |
| Total | 0.72 | 0 | NC* |

Lung and Bronchus

| | | | |
|--------|-------|----|-----|
| Male | 7.80 | 6 | 77 |
| Female | 5.54 | 8 | 144 |
| Total | 13.33 | 14 | 105 |

| | | | |
|--------|------|---|-----|
| Female | 0.87 | 1 | NC* |
| Total | 1.84 | 3 | NC* |

Prostate

| | | | |
|------|-------|----|-----|
| Male | 14.80 | 18 | 122 |
|------|-------|----|-----|

Stomach

| | | | |
|--------|------|---|-----|
| Male | 1.03 | 0 | NC* |
| Female | 0.53 | 0 | NC* |
| Total | 1.56 | 0 | NC* |

Testis

| | | | |
|------|------|---|-----|
| Male | 0.57 | 1 | NC* |
|------|------|---|-----|

Thyroid

| | | | |
|--------|------|---|-----|
| Male | 0.32 | 0 | NC* |
| Female | 0.77 | 1 | NC* |
| Total | 1.09 | 1 | NC* |

Uteri, Corpus and Uterus, NOS

| | | | |
|--------|------|---|-----|
| Female | 2.70 | 5 | 185 |
|--------|------|---|-----|

All Sites / Types

| | | | |
|--------|-------|----|-----|
| Male | 49.06 | 55 | 112 |
| Female | 42.21 | 42 | 99 |
| Total | 91.28 | 97 | 106 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Braintree

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|-------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | |
| Male | 24.37 | 32 | 131 |
| Female | 10.04 | 17 | 169 |
| Total | 34.41 | 49 | 142 #+ |

Brain and Other Central Nervous System

| | | | |
|--------|-------|----|-----|
| Male | 7.36 | 3 | NC* |
| Female | 6.14 | 7 | 114 |
| Total | 13.50 | 10 | 74 |

Breast

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|-------------------------|------------|------------|------------|
| <u>Melanoma of Skin</u> | | | |
| Male | 14.49 | 21 | 145 |
| Female | 11.59 | 18 | 155 |
| Total | 26.09 | 39 | 149 #+ |

Multiple Myeloma

| | | | |
|--------|------|---|-----|
| Male | 4.51 | 4 | NC* |
| Female | 4.33 | 2 | NC* |
| Total | 8.84 | 6 | 68 |

Non-Hodgkin's Lymphoma

| | | | |
|--------|--------|-----|--------|
| Male | 1.53 | 3 | NC* |
| Female | 150.52 | 185 | 123 ~+ |
| Total | 152.05 | 188 | 124 ~+ |

Cervix Uteri

| | | | |
|--------|------|---|----|
| Female | 8.62 | 8 | 93 |
|--------|------|---|----|

Colon / Rectum

| | | | |
|--------|--------|-----|--------|
| Male | 61.07 | 65 | 106 |
| Female | 62.91 | 84 | 134 #+ |
| Total | 123.99 | 149 | 120 #+ |

Esophagus

| | | | |
|--------|-------|----|--------|
| Male | 8.57 | 15 | 175 |
| Female | 3.26 | 5 | 153 |
| Total | 11.83 | 20 | 169 #+ |

Hodgkin's Disease

| | | | |
|--------|------|---|-----|
| Male | 3.38 | 1 | NC* |
| Female | 2.82 | 6 | 213 |
| Total | 6.20 | 7 | 113 |

Kidney and Renal Pelvis

| | | | |
|--------|-------|----|-----|
| Male | 13.54 | 14 | 103 |
| Female | 9.02 | 8 | 89 |
| Total | 22.56 | 22 | 98 |

Larynx

| | | | |
|--------|------|---|-----|
| Male | 7.78 | 5 | 64 |
| Female | 2.21 | 2 | NC* |
| Total | 9.99 | 7 | 70 |

Leukemia

| | | | |
|--------|-------|----|-----|
| Male | 10.08 | 9 | 89 |
| Female | 8.33 | 14 | 168 |
| Total | 18.41 | 23 | 125 |

Liver and Intrahepatic Bile Ducts

| | | | |
|--------|------|---|-----|
| Male | 5.01 | 6 | 120 |
| Female | 2.28 | 2 | NC* |
| Total | 7.30 | 8 | 110 |

Lung and Bronchus

| | | | |
|--------|--------|-----|--------|
| Male | 76.63 | 101 | 132 ~+ |
| Female | 62.89 | 85 | 135 ~+ |
| Total | 139.52 | 186 | 133 ^+ |

| | | | |
|--------|-------|----|-----|
| Male | 18.47 | 19 | 103 |
| Female | 17.83 | 18 | 101 |
| Total | 36.30 | 37 | 102 |

Oral Cavity and Pharynx

| | | | |
|--------|-------|----|-----|
| Male | 14.76 | 16 | 108 |
| Female | 7.55 | 11 | 146 |
| Total | 22.31 | 27 | 121 |

Ovary

| | | | |
|--------|-------|----|----|
| Female | 17.53 | 13 | 74 |
|--------|-------|----|----|

Pancreas

| | | | |
|--------|-------|----|-----|
| Male | 9.45 | 14 | 148 |
| Female | 10.95 | 10 | 91 |
| Total | 20.40 | 24 | 118 |

Prostate

| | | | |
|------|--------|-----|-----|
| Male | 145.02 | 168 | 116 |
|------|--------|-----|-----|

Stomach

| | | | |
|--------|-------|----|----|
| Male | 10.18 | 10 | 98 |
| Female | 6.78 | 5 | 74 |
| Total | 16.96 | 15 | 88 |

Testis

| | | | |
|------|------|---|----|
| Male | 5.04 | 5 | 99 |
|------|------|---|----|

Thyroid

| | | | |
|--------|-------|---|-----|
| Male | 2.79 | 2 | NC* |
| Female | 7.58 | 7 | 92 |
| Total | 10.36 | 9 | 87 |

Uteri, Corpus and Uterus, NOS

| | | | |
|--------|-------|----|-----|
| Female | 29.00 | 31 | 107 |
|--------|-------|----|-----|

All Sites / Types

| | | | |
|--------|--------|------|--------|
| Male | 476.37 | 549 | 115 ~+ |
| Female | 477.67 | 574 | 120 ^+ |
| Total | 954.04 | 1123 | 118 ^+ |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Brewster

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 11.04 | 11 | 100 | Male | 5.65 | 11 | 195 |
| Female | 3.48 | 3 | NC* | Female | 3.63 | 8 | 220 |
| Total | 14.52 | 14 | 96 | Total | 9.29 | 19 | 205 ~+ |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 2.67 | 0 | NC* | Male | 1.98 | 1 | NC* |
| Female | 1.99 | 3 | NC* | Female | 1.49 | 0 | NC* |
| Total | 4.66 | 3 | NC* | Total | 3.47 | 1 | NC* |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 0.66 | 3 | NC* | Male | 7.29 | 6 | 82 |
| Female | 49.22 | 70 | 142 ~+ | Female | 6.03 | 5 | 83 |
| Total | 49.88 | 73 | 146 ~+ | Total | 13.31 | 11 | 83 |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 2.54 | 3 | NC* | Male | 5.69 | 3 | NC* |
| | | | | Female | 2.52 | 1 | NC* |
| | | | | Total | 8.22 | 4 | NC* |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 27.26 | 18 | 66 | Female | 5.66 | 1 | NC* |
| Female | 21.86 | 12 | 55 #- | | | | |
| Total | 49.12 | 30 | 61 ~- | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 3.55 | 2 | NC* | Male | 4.07 | 3 | NC* |
| Female | 1.14 | 0 | NC* | Female | 3.82 | 2 | NC* |
| Total | 4.69 | 2 | NC* | Total | 7.88 | 5 | 63 |
| <u>Hodgkin's Disease</u> | | | | <u>Prostate</u> | | | |
| Male | 0.97 | 0 | NC* | Male | 61.67 | 77 | 125 |
| Female | 0.81 | 1 | NC* | | | | |
| Total | 1.77 | 1 | NC* | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | <u>Stomach</u> | | | |
| Male | 5.47 | 4 | NC* | Male | 4.51 | 2 | NC* |
| Female | 3.07 | 3 | NC* | Female | 2.33 | 1 | NC* |
| Total | 8.55 | 7 | 82 | Total | 6.83 | 3 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 3.10 | 3 | NC* | Male | 1.20 | 0 | NC* |
| Female | 0.75 | 0 | NC* | | | | |
| Total | 3.86 | 3 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 4.08 | 7 | 172 | Male | 0.87 | 1 | NC* |
| Female | 2.74 | 0 | NC* | Female | 2.16 | 1 | NC* |
| Total | 6.82 | 7 | 103 | Total | 3.03 | 2 | NC* |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Male | 2.03 | 1 | NC* | Female | 9.66 | 11 | 114 |
| Female | 0.79 | 2 | NC* | | | | |
| Total | 2.82 | 3 | NC* | | | | |
| <u>Lung and Bronchus</u> | | | | <u>All Sites / Types</u> | | | |
| Male | 32.79 | 19 | 58 #- | Male | 200.09 | 182 | 91 |
| Female | 21.85 | 30 | 137 | Female | 159.49 | 166 | 104 |
| Total | 54.64 | 49 | 90 | Total | 359.58 | 348 | 97 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Bridgewater

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---------------------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 10.98 | 14 | 127 | Male | 8.67 | 3 | NC* |
| Female | 3.67 | 5 | 136 | Female | 5.66 | 6 | 106 |
| Total | 14.66 | 19 | 130 | Total | 14.33 | 9 | 63 |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 4.77 | 5 | 105 | Male | 2.18 | 1 | NC* |
| Female | 3.02 | 1 | NC* | Female | 1.70 | 3 | NC* |
| Total | 7.79 | 6 | 77 | Total | 3.88 | 4 | NC* |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 0.76 | 0 | NC* | Male | 10.84 | 8 | 74 |
| Female | 67.77 | 61 | 90 | Female | 7.40 | 8 | 108 |
| Total | 68.53 | 61 | 89 | Total | 18.24 | 16 | 88 |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 4.74 | 8 | 169 | Male | 8.83 | 5 | 57 |
| <u>Colon / Rectum</u> | | | | Female | 3.20 | 1 | NC* |
| Male | 27.93 | 19 | 68 | Total | 12.03 | 6 | 50 |
| Female | 22.98 | 14 | 61 | <u>Ovary</u> | | | |
| Total | 50.91 | 33 | 65 #- | Female | 8.18 | 15 | 183 #+ |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 4.45 | 9 | 202 | Male | 4.64 | 1 | NC* |
| Female | 1.16 | 1 | NC* | Female | 3.98 | 5 | 126 |
| Total | 5.61 | 10 | 178 | Total | 8.62 | 6 | 70 |
| <u>Hodgkin's Disease</u> | | | | <u>Prostate</u> | | | |
| Male | 2.85 | 0 | NC* | Male | 69.00 | 71 | 103 |
| Female | 1.71 | 2 | NC* | <u>Stomach</u> | | | |
| Total | 4.56 | 2 | NC* | Male | 4.87 | 4 | NC* |
| <u>Kidney and Renal Pelvis</u> | | | | Female | 2.51 | 2 | NC* |
| Male | 7.50 | 8 | 107 | Total | 7.38 | 6 | 81 |
| Female | 3.76 | 5 | 133 | <u>Testis</u> | | | |
| Total | 11.26 | 13 | 115 | Male | 4.86 | 5 | 103 |
| <u>Larynx</u> | | | | | | | |
| Male | 4.30 | 4 | NC* | | | | |
| Female | 0.95 | 0 | NC* | | | | |

| | | | |
|---|-------|----|-----|
| Total | 5.25 | 4 | NC* |
| <u>Leukemia</u> | | | |
| Male | 5.66 | 7 | 124 |
| Female | 3.82 | 3 | NC* |
| Total | 9.48 | 10 | 106 |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | |
| Male | 2.73 | 3 | NC* |
| Female | 0.88 | 0 | NC* |
| Total | 3.60 | 3 | NC* |
| <u>Lung and Bronchus</u> | | | |
| Male | 37.06 | 40 | 108 |
| Female | 25.13 | 25 | 99 |
| Total | 62.19 | 65 | 105 |

| | | | |
|---|--------|-----|-----|
| <u>Thyroid</u> | | | |
| Male | 2.15 | 1 | NC* |
| Female | 4.45 | 6 | 135 |
| Total | 6.60 | 7 | 106 |
| <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Female | 12.68 | 14 | 110 |
| <u>All Sites / Types</u> | | | |
| Male | 242.32 | 222 | 92 |
| Female | 203.66 | 200 | 98 |
| Total | 445.98 | 422 | 95 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Brimfield

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---------------------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 2.20 | 4 | NC* | Male | 1.36 | 0 | NC* |
| Female | 0.80 | 3 | NC* | Female | 0.99 | 2 | NC* |
| Total | 3.00 | 7 | 234 | Total | 2.35 | 2 | NC* |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 0.69 | 0 | NC* | Male | 0.41 | 0 | NC* |
| Female | 0.53 | 1 | NC* | Female | 0.36 | 0 | NC* |
| Total | 1.22 | 1 | NC* | Total | 0.77 | 0 | NC* |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 0.14 | 0 | NC* | Male | 1.71 | 1 | NC* |
| Female | 12.93 | 19 | 147 | Female | 1.46 | 2 | NC* |
| Total | 13.07 | 19 | 145 | Total | 3.17 | 3 | NC* |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 0.74 | 2 | NC* | Male | 1.43 | 2 | NC* |
| | | | | Female | 0.64 | 0 | NC* |
| | | | | Total | 2.06 | 2 | NC* |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 5.45 | 2 | NC* | | | | |
| Female | 4.99 | 6 | 120 | Female | 1.51 | 0 | NC* |
| Total | 10.44 | 8 | 77 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.80 | 0 | NC* | Male | 0.87 | 1 | NC* |

| | | | |
|---------------------------------|------|---|-----|
| Female | 0.26 | 0 | NC* |
| Total | 1.06 | 0 | NC* |
| <u>Hodgkin's Disease</u> | | | |
| Male | 0.31 | 0 | NC* |
| Female | 0.24 | 0 | NC* |
| Total | 0.54 | 0 | NC* |

| | | | |
|---------------------------------------|------|---|-----|
| <u>Kidney and Renal Pelvis</u> | | | |
| Male | 1.27 | 2 | NC* |
| Female | 0.75 | 1 | NC* |
| Total | 2.02 | 3 | NC* |

| | | | |
|----------------------|------|---|-----|
| <u>Larynx</u> | | | |
| Male | 0.73 | 0 | NC* |
| Female | 0.19 | 1 | NC* |
| Total | 0.92 | 1 | NC* |

| | | | |
|------------------------|------|---|-----|
| <u>Leukemia</u> | | | |
| Male | 0.95 | 2 | NC* |
| Female | 0.71 | 1 | NC* |
| Total | 1.65 | 3 | NC* |

| | | | |
|---|------|---|-----|
| <u>Liver and Intrahepatic Bile Ducts</u> | | | |
| Male | 0.47 | 0 | NC* |
| Female | 0.18 | 1 | NC* |
| Total | 0.65 | 1 | NC* |

| | | | |
|---------------------------------|-------|----|-----|
| <u>Lung and Bronchus</u> | | | |
| Male | 6.84 | 6 | 88 |
| Female | 5.20 | 6 | 115 |
| Total | 12.04 | 12 | 100 |

| | | | |
|------------------------|-------|---|-----|
| Female | 0.87 | 1 | NC* |
| Total | 1.74 | 2 | NC* |
| <u>Prostate</u> | | | |
| Male | 12.89 | 9 | 70 |

| | | | |
|-----------------------|------|---|-----|
| <u>Stomach</u> | | | |
| Male | 0.94 | 1 | NC* |
| Female | 0.54 | 1 | NC* |
| Total | 1.47 | 2 | NC* |

| | | | |
|----------------------|------|---|-----|
| <u>Testis</u> | | | |
| Male | 0.43 | 0 | NC* |

| | | | |
|-----------------------|------|---|-----|
| <u>Thyroid</u> | | | |
| Male | 0.26 | 0 | NC* |
| Female | 0.65 | 1 | NC* |
| Total | 0.91 | 1 | NC* |

| | | | |
|---|------|---|-----|
| <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Female | 2.50 | 3 | NC* |

| | | | |
|---------------------------------|-------|----|--------|
| <u>All Sites / Types</u> | | | |
| Male | 43.08 | 32 | 74 |
| Female | 39.90 | 55 | 138 #+ |
| Total | 82.98 | 87 | 105 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Brockton

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--------------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | |
| Male | 52.28 | 81 | 155 ^+ |
| Female | 21.84 | 26 | 119 |
| Total | 74.12 | 107 | 144 ^+ |

| | | | |
|--|-------|----|-----|
| <u>Brain and Other Central Nervous System</u> | | | |
| Male | 17.06 | 21 | 123 |
| Female | 14.37 | 10 | 70 |
| Total | 31.43 | 31 | 99 |

Breast

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--------------------------------|------------|------------|------------|
| <u>Melanoma of Skin</u> | | | |
| Male | 32.30 | 36 | 111 |
| Female | 26.74 | 25 | 93 |
| Total | 59.04 | 61 | 103 |

| | | | |
|--------------------------------|-------|----|-----|
| <u>Multiple Myeloma</u> | | | |
| Male | 9.67 | 12 | 124 |
| Female | 9.42 | 14 | 149 |
| Total | 19.09 | 26 | 136 |

Non-Hodgkin's Lymphoma

| | | | |
|--------|--------|-----|-------|
| Male | 3.30 | 1 | NC* |
| Female | 333.91 | 300 | 90 |
| Total | 337.20 | 301 | 89 #- |

Cervix Uteri

| | | | |
|--------|-------|----|--------|
| Female | 20.50 | 41 | 200 ^+ |
|--------|-------|----|--------|

Colon / Rectum

| | | | |
|--------|--------|-----|-----|
| Male | 130.59 | 135 | 103 |
| Female | 137.32 | 118 | 86 |
| Total | 267.91 | 253 | 94 |

Esophagus

| | | | |
|--------|-------|----|--------|
| Male | 18.44 | 23 | 125 |
| Female | 7.07 | 14 | 198 #+ |
| Total | 25.51 | 37 | 145 #+ |

Hodgkin's Disease

| | | | |
|--------|-------|----|-----|
| Male | 8.46 | 7 | 83 |
| Female | 7.23 | 8 | 111 |
| Total | 15.70 | 15 | 96 |

Kidney and Renal Pelvis

| | | | |
|--------|-------|----|----|
| Male | 29.55 | 21 | 71 |
| Female | 19.78 | 18 | 91 |
| Total | 49.32 | 39 | 79 |

Larynx

| | | | |
|--------|-------|----|-----|
| Male | 16.80 | 20 | 119 |
| Female | 4.75 | 7 | 147 |
| Total | 21.55 | 27 | 125 |

Leukemia

| | | | |
|--------|-------|----|-----|
| Male | 23.07 | 29 | 126 |
| Female | 19.47 | 14 | 72 |
| Total | 42.55 | 43 | 101 |

Liver and Intrahepatic Bile Ducts

| | | | |
|--------|-------|----|-----|
| Male | 10.91 | 14 | 128 |
| Female | 5.00 | 8 | 160 |
| Total | 15.91 | 22 | 138 |

Lung and Bronchus

| | | | |
|--------|--------|-----|--------|
| Male | 162.84 | 234 | 144 ^+ |
| Female | 135.26 | 180 | 133 ^+ |
| Total | 298.10 | 414 | 139 ^+ |

| | | | |
|--------|-------|----|-----|
| Male | 41.47 | 42 | 101 |
| Female | 39.67 | 31 | 78 |
| Total | 81.14 | 73 | 90 |

Oral Cavity and Pharynx

| | | | |
|--------|-------|----|-----|
| Male | 32.55 | 43 | 132 |
| Female | 16.65 | 14 | 84 |
| Total | 49.20 | 57 | 116 |

Ovary

| | | | |
|--------|-------|----|----|
| Female | 39.40 | 37 | 94 |
|--------|-------|----|----|

Pancreas

| | | | |
|--------|-------|----|----|
| Male | 20.36 | 18 | 88 |
| Female | 23.66 | 18 | 76 |
| Total | 44.02 | 36 | 82 |

Prostate

| | | | |
|------|--------|-----|-----|
| Male | 305.73 | 305 | 100 |
|------|--------|-----|-----|

Stomach

| | | | |
|--------|-------|----|-----|
| Male | 22.08 | 26 | 118 |
| Female | 14.91 | 15 | 101 |
| Total | 37.00 | 41 | 111 |

Testis

| | | | |
|------|-------|----|-----|
| Male | 12.86 | 18 | 140 |
|------|-------|----|-----|

Thyroid

| | | | |
|--------|-------|----|----|
| Male | 6.54 | 6 | 92 |
| Female | 18.64 | 17 | 91 |
| Total | 25.18 | 23 | 91 |

Uteri, Corpus and Uterus, NOS

| | | | |
|--------|-------|----|-----|
| Female | 63.33 | 64 | 101 |
|--------|-------|----|-----|

All Sites / Types

| | | | |
|--------|---------|------|--------|
| Male | 1028.86 | 1179 | 115 ^+ |
| Female | 1058.28 | 1046 | 99 |
| Total | 2087.14 | 2225 | 107 ~+ |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Brookfield

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 1.98 | 5 | 253 | Male | 1.20 | 2 | NC* |
| Female | 0.80 | 1 | NC* | Female | 0.94 | 0 | NC* |
| Total | 2.78 | 6 | 216 | Total | 2.15 | 2 | NC* |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 0.63 | 0 | NC* | Male | 0.37 | 0 | NC* |
| Female | 0.52 | 0 | NC* | Female | 0.35 | 0 | NC* |
| Total | 1.15 | 0 | NC* | Total | 0.72 | 0 | NC* |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 0.13 | 0 | NC* | Male | 1.53 | 4 | NC* |
| Female | 12.18 | 13 | 107 | Female | 1.46 | 1 | NC* |
| Total | 12.31 | 13 | 106 | Total | 2.99 | 5 | 167 |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 0.70 | 3 | NC* | Male | 1.24 | 2 | NC* |
| | | | | Female | 0.61 | 1 | NC* |
| | | | | Total | 1.85 | 3 | NC* |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 4.96 | 5 | 101 | Female | 1.43 | 1 | NC* |
| Female | 5.06 | 3 | NC* | | | | |
| Total | 10.01 | 8 | 80 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.71 | 3 | NC* | Male | 0.78 | 1 | NC* |
| Female | 0.26 | 0 | NC* | Female | 0.88 | 2 | NC* |
| Total | 0.97 | 3 | NC* | Total | 1.65 | 3 | NC* |
| <u>Hodgkin's Disease</u> | | | | <u>Prostate</u> | | | |
| Male | 0.29 | 0 | NC* | Male | 11.82 | 6 | 51 |
| Female | 0.24 | 1 | NC* | | | | |
| Total | 0.53 | 1 | NC* | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | <u>Stomach</u> | | | |
| Male | 1.12 | 2 | NC* | Male | 0.83 | 0 | NC* |
| Female | 0.74 | 1 | NC* | Female | 0.54 | 0 | NC* |
| Total | 1.86 | 3 | NC* | Total | 1.37 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.65 | 2 | NC* | Male | 0.43 | 2 | NC* |
| Female | 0.18 | 1 | NC* | | | | |
| Total | 0.83 | 3 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.85 | 1 | NC* | Male | 0.24 | 0 | NC* |
| Female | 0.70 | 2 | NC* | Female | 0.63 | 4 | NC* |
| Total | 1.55 | 3 | NC* | Total | 0.86 | 4 | NC* |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Male | 0.42 | 0 | NC* | Female | 2.35 | 0 | NC* |
| Female | 0.19 | 2 | NC* | | | | |
| Total | 0.60 | 2 | NC* | | | | |
| <u>Lung and Bronchus</u> | | | | <u>All Sites / Types</u> | | | |
| Male | 6.24 | 9 | 144 | Male | 39.06 | 46 | 118 |
| Female | 5.18 | 4 | NC* | Female | 38.82 | 40 | 103 |
| Total | 11.43 | 13 | 114 | Total | 77.89 | 86 | 110 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs / Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Brookline

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---------------------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 34.04 | 28 | 82 | Male | 21.64 | 25 | 116 |
| Female | 16.65 | 9 | 54 | Female | 21.00 | 30 | 143 |
| Total | 50.68 | 37 | 73 | Total | 42.64 | 55 | 129 |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 10.95 | 14 | 128 | Male | 6.27 | 5 | 80 |
| Female | 10.36 | 11 | 106 | Female | 7.00 | 5 | 71 |
| Total | 21.31 | 25 | 117 | Total | 13.27 | 10 | 75 |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 2.16 | 2 | NC* | Male | 27.54 | 35 | 127 |
| Female | 253.84 | 280 | 110 | Female | 29.81 | 36 | 121 |
| Total | 256.00 | 282 | 110 | Total | 57.35 | 71 | 124 |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 16.58 | 13 | 78 | Male | 21.64 | 19 | 88 |
| | | | | Female | 12.55 | 13 | 104 |
| | | | | Total | 34.19 | 32 | 94 |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 84.55 | 97 | 115 | Female | 29.97 | 26 | 87 |
| Female | 104.58 | 108 | 103 | | | | |
| Total | 189.13 | 205 | 108 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 12.03 | 5 | 42 #- | Male | 13.32 | 13 | 98 |
| Female | 5.39 | 3 | NC* | Female | 17.87 | 12 | 67 |
| Total | 17.42 | 8 | 46 #- | Total | 31.18 | 25 | 80 |
| <u>Hodgkin's Disease</u> | | | | <u>Prostate</u> | | | |
| Male | 5.75 | 8 | 139 | Male | 194.36 | 223 | 115 #+ |
| Female | 5.69 | 8 | 141 | | | | |
| Total | 11.43 | 16 | 140 | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | <u>Stomach</u> | | | |
| Male | 19.25 | 14 | 73 | Male | 14.56 | 12 | 82 |
| Female | 14.46 | 10 | 69 | Female | 11.58 | 10 | 86 |
| Total | 33.71 | 24 | 71 | Total | 26.14 | 22 | 84 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 10.97 | 8 | 73 | Male | 9.26 | 6 | 65 |
| Female | 3.42 | 1 | NC* | | | | |

| | | | |
|------------------------|-------|----|-----|
| Total | 14.39 | 9 | 63 |
| <u>Leukemia</u> | | | |
| Male | 14.58 | 17 | 117 |
| Female | 14.16 | 14 | 99 |
| Total | 28.75 | 31 | 108 |

Liver and Intrahepatic Bile Ducts

| | | | |
|--------|-------|----|-----|
| Male | 7.12 | 8 | 112 |
| Female | 3.68 | 5 | 136 |
| Total | 10.80 | 13 | 120 |

Lung and Bronchus

| | | | |
|--------|--------|-----|-------|
| Male | 104.35 | 83 | 80 #- |
| Female | 97.63 | 64 | 66 ^- |
| Total | 201.97 | 147 | 73 ^- |

Thyroid

| | | | |
|--------|-------|----|-----|
| Male | 4.54 | 8 | 176 |
| Female | 15.18 | 18 | 119 |
| Total | 19.72 | 26 | 132 |

Uteri, Corpus and Uterus, NOS

| | | | |
|--------|-------|----|----|
| Female | 47.08 | 45 | 96 |
|--------|-------|----|----|

All Sites / Types

| | | | |
|--------|---------|------|-----|
| Male | 665.86 | 678 | 102 |
| Female | 799.09 | 776 | 97 |
| Total | 1464.95 | 1454 | 99 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Buckland

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------|------------|---------------------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | | <u>Melanoma of Skin</u> | | | |
| Male | 1.35 | 1 | NC* | Male | 0.82 | 0 | NC* |
| Female | 0.46 | 1 | NC* | Female | 0.57 | 0 | NC* |
| Total | 1.81 | 2 | NC* | Total | 1.39 | 0 | NC* |
| <u>Brain and Other Central Nervous System</u> | | | | <u>Multiple Myeloma</u> | | | |
| Male | 0.42 | 1 | NC* | Male | 0.25 | 1 | NC* |
| Female | 0.30 | 1 | NC* | Female | 0.21 | 1 | NC* |
| Total | 0.72 | 2 | NC* | Total | 0.46 | 2 | NC* |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Lymphoma</u> | | | |
| Male | 0.09 | 0 | NC* | Male | 1.03 | 0 | NC* |
| Female | 7.37 | 8 | 109 | Female | 0.84 | 2 | NC* |
| Total | 7.46 | 8 | 107 | Total | 1.88 | 2 | NC* |
| <u>Cervix Uteri</u> | | | | <u>Oral Cavity and Pharynx</u> | | | |
| Female | 0.43 | 0 | NC* | Male | 0.85 | 1 | NC* |
| | | | | Female | 0.36 | 0 | NC* |
| | | | | Total | 1.21 | 1 | NC* |
| <u>Colon / Rectum</u> | | | | <u>Ovary</u> | | | |
| Male | 3.38 | 5 | 148 | Female | 0.86 | 0 | NC* |
| Female | 2.89 | 2 | NC* | | | | |
| Total | 6.27 | 7 | 112 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.49 | 0 | NC* | Male | 0.53 | 0 | NC* |

| | | | |
|---------------------------------|------|---|-----|
| Female | 0.15 | 0 | NC* |
| Total | 0.63 | 0 | NC* |
| <u>Hodgkin's Disease</u> | | | |
| Male | 0.18 | 0 | NC* |
| Female | 0.14 | 0 | NC* |
| Total | 0.32 | 0 | NC* |

| | | | |
|---------------------------------------|------|---|-----|
| <u>Kidney and Renal Pelvis</u> | | | |
| Male | 0.77 | 1 | NC* |
| Female | 0.43 | 0 | NC* |
| Total | 1.20 | 1 | NC* |

| | | | |
|----------------------|------|---|-----|
| <u>Larynx</u> | | | |
| Male | 0.45 | 0 | NC* |
| Female | 0.11 | 0 | NC* |
| Total | 0.55 | 0 | NC* |

| | | | |
|------------------------|------|---|-----|
| <u>Leukemia</u> | | | |
| Male | 0.57 | 0 | NC* |
| Female | 0.41 | 0 | NC* |
| Total | 0.97 | 0 | NC* |

| | | | |
|---|------|---|-----|
| <u>Liver and Intrahepatic Bile Ducts</u> | | | |
| Male | 0.28 | 0 | NC* |
| Female | 0.11 | 0 | NC* |
| Total | 0.39 | 0 | NC* |

| | | | |
|---------------------------------|------|---|-----|
| <u>Lung and Bronchus</u> | | | |
| Male | 4.28 | 2 | NC* |
| Female | 2.98 | 2 | NC* |
| Total | 7.26 | 4 | NC* |

| | | | |
|--------|------|---|-----|
| Female | 0.50 | 1 | NC* |
| Total | 1.03 | 1 | NC* |

| | | | |
|------------------------|------|---|-----|
| <u>Prostate</u> | | | |
| Male | 8.10 | 3 | NC* |

| | | | |
|-----------------------|------|---|-----|
| <u>Stomach</u> | | | |
| Male | 0.57 | 0 | NC* |
| Female | 0.31 | 0 | NC* |
| Total | 0.88 | 0 | NC* |

| | | | |
|----------------------|------|---|-----|
| <u>Testis</u> | | | |
| Male | 0.26 | 1 | NC* |

| | | | |
|-----------------------|------|---|-----|
| <u>Thyroid</u> | | | |
| Male | 0.16 | 0 | NC* |
| Female | 0.38 | 0 | NC* |
| Total | 0.54 | 0 | NC* |

| | | | |
|---|------|---|-----|
| <u>Uteri, Corpus and Uterus, NOS</u> | | | |
| Female | 1.42 | 2 | NC* |

| | | | |
|---------------------------------|-------|----|----|
| <u>All Sites / Types</u> | | | |
| Male | 26.61 | 19 | 71 |
| Female | 22.90 | 22 | 96 |
| Total | 49.51 | 41 | 83 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels

Burlington

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--------------------------------|------------|------------|------------|
| <u>Bladder, Urinary</u> | | | |
| Male | 13.49 | 15 | 111 |
| Female | 4.65 | 5 | 108 |
| Total | 18.14 | 20 | 110 |

| | | | |
|--|------|---|-----|
| <u>Brain and Other Central Nervous System</u> | | | |
| Male | 5.07 | 5 | 99 |
| Female | 3.79 | 1 | NC* |
| Total | 8.86 | 6 | 68 |

Breast

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--------------------------------|------------|------------|------------|
| <u>Melanoma of Skin</u> | | | |
| Male | 9.39 | 9 | 96 |
| Female | 7.19 | 11 | 153 |
| Total | 16.58 | 20 | 121 |

| | | | |
|--------------------------------|------|---|-----|
| <u>Multiple Myeloma</u> | | | |
| Male | 2.62 | 1 | NC* |
| Female | 2.25 | 4 | NC* |
| Total | 4.86 | 5 | 103 |

Non-Hodgkin's Lymphoma

| | | | |
|--------|-------|----|-----|
| Male | 0.90 | 2 | NC* |
| Female | 90.27 | 80 | 89 |
| Total | 91.17 | 82 | 90 |

Cervix Uteri

| | | | |
|--------|------|---|-----|
| Female | 6.00 | 6 | 100 |
|--------|------|---|-----|

Colon / Rectum

| | | | |
|--------|-------|----|-----|
| Male | 34.65 | 35 | 101 |
| Female | 28.77 | 22 | 76 |
| Total | 63.42 | 57 | 90 |

Esophagus

| | | | |
|--------|------|---|-----|
| Male | 5.37 | 2 | NC* |
| Female | 1.47 | 0 | NC* |
| Total | 6.84 | 2 | NC* |

Hodgkin's Disease

| | | | |
|--------|------|---|-----|
| Male | 2.58 | 2 | NC* |
| Female | 1.99 | 2 | NC* |
| Total | 4.57 | 4 | NC* |

Kidney and Renal Pelvis

| | | | |
|--------|-------|----|-----|
| Male | 8.64 | 6 | 69 |
| Female | 5.03 | 4 | NC* |
| Total | 13.67 | 10 | 73 |

Larynx

| | | | |
|--------|------|---|-----|
| Male | 5.09 | 4 | NC* |
| Female | 1.34 | 4 | NC* |
| Total | 6.44 | 8 | 124 |

Leukemia

| | | | |
|--------|-------|----|-----|
| Male | 6.26 | 11 | 176 |
| Female | 4.57 | 3 | NC* |
| Total | 10.82 | 14 | 129 |

Liver and Intrahepatic Bile Ducts

| | | | |
|--------|------|---|-----|
| Male | 3.19 | 3 | NC* |
| Female | 1.13 | 1 | NC* |
| Total | 4.33 | 4 | NC* |

Lung and Bronchus

| | | | |
|--------|-------|----|-------|
| Male | 46.42 | 53 | 114 |
| Female | 34.70 | 20 | 58 #- |
| Total | 81.12 | 73 | 90 |

| | | | |
|--------|-------|----|-----|
| Male | 11.74 | 12 | 102 |
| Female | 9.50 | 10 | 105 |
| Total | 21.24 | 22 | 104 |

Oral Cavity and Pharynx

| | | | |
|--------|-------|---|-----|
| Male | 9.87 | 4 | NC* |
| Female | 4.20 | 5 | 119 |
| Total | 14.08 | 9 | 64 |

Ovary

| | | | |
|--------|-------|---|----|
| Female | 10.78 | 8 | 74 |
|--------|-------|---|----|

Pancreas

| | | | |
|--------|-------|----|-----|
| Male | 5.63 | 9 | 160 |
| Female | 5.14 | 6 | 117 |
| Total | 10.77 | 15 | 139 |

Prostate

| | | | |
|------|-------|-----|-----|
| Male | 89.37 | 105 | 117 |
|------|-------|-----|-----|

Stomach

| | | | |
|--------|------|----|-----|
| Male | 5.78 | 7 | 121 |
| Female | 3.07 | 7 | 228 |
| Total | 8.85 | 14 | 158 |

Testis

| | | | |
|------|------|---|-----|
| Male | 4.09 | 6 | 147 |
|------|------|---|-----|

Thyroid

| | | | |
|--------|------|---|--------|
| Male | 2.09 | 6 | 288 #+ |
| Female | 5.47 | 3 | NC* |
| Total | 7.56 | 9 | 119 |

Uteri, Corpus and Uterus, NOS

| | | | |
|--------|-------|----|-----|
| Female | 17.30 | 18 | 104 |
|--------|-------|----|-----|

All Sites / Types

| | | | |
|--------|--------|-----|-------|
| Male | 291.65 | 318 | 109 |
| Female | 266.26 | 228 | 86 #- |
| Total | 557.91 | 546 | 98 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [**Obs** / **Exp**) X 100]

* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

indicates statistical significance at the $p \leq 0.05$ level

~ indicates statistical significance at the $p \leq 0.01$ level, as well as at the $p \leq 0.05$ level

^ indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.01$ and $p \leq 0.05$ levels